View Past PerformanceDenka バランスシートの健全性財務の健全性 基準チェック /36Denkaの総株主資本は¥312.6B 、総負債は¥222.1Bで、負債比率は71.1%となります。総資産と総負債はそれぞれ¥655.2Bと¥342.6Bです。 Denkaの EBIT は¥20.8Bで、利息カバレッジ比率22.4です。現金および短期投資は¥30.4Bです。主要情報71.05%負債資本比率JP¥222.09b負債インタレスト・カバレッジ・レシオ22.4x現金JP¥30.40bエクイティJP¥312.56b負債合計JP¥342.63b総資産JP¥655.20b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 13Denka Company Limited, Annual General Meeting, Jun 19, 2026Denka Company Limited, Annual General Meeting, Jun 19, 2026.お知らせ • Apr 22+ 3 more updatesDenka Company Limited to Report Q2, 2027 Results on Nov 09, 2026Denka Company Limited announced that they will report Q2, 2027 results on Nov 09, 2026お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.お知らせ • Mar 10Denka Company Limited (TSE:4061) enter into a share transfer agreement to acquire an additional 15% stake in Toyo Styrene Co. Ltd from Daicel Corporation (TSE:4202).Denka Company Limited (TSE:4061) enter into a share transfer agreement to acquire an additional 15% stake in Toyo Styrene Co. Ltd from Daicel Corporation (TSE:4202) on March 9, 2026. Upon completion, Denka Company Limited will own 65% stake in Toyo Styrene Co. Ltd. As a result of this transaction, Toyo Styrene is expected to become a consolidated subsidiary of the Company that qualifies as a specified subsidiary. Daicel will cease to be a co-investor in Toyo Styrene, and Toyo Styrene’s Hirohata Plant will be shut down. For a certain period, however, Toyo Styrene will continue to outsource production to Daicel and maintain product sales. For the period ending March 31, 2025, Toyo Styrene Co. Ltd reported total revenue of ¥48.39 billion, EBIT of ¥1.22 billion and net income of ¥788 million. As of March 31, 2025, Toyo Styrene Co. Ltd reported total assets of ¥27.69 billion and total common equity of ¥11.73 billion. The completion of this share transfer is subject to the completion of the necessary approvals, permissions, or clearances from the relevant authorities in accordance with the Anti-Monopoly Act and other applicable laws and regulations. The expected completion of the transaction is March 31, 2026.お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.お知らせ • Dec 24Denka Company Limited to Report Q3, 2026 Results on Feb 06, 2026Denka Company Limited announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 22Denka Company Limited(TSE:4061) dropped from FTSE All-World Index (USD)Denka Company Limited(TSE:4061) dropped from FTSE All-World Index (USD)お知らせ • Sep 03Denka Company Limited to Report Q2, 2026 Results on Nov 10, 2025Denka Company Limited announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • Jul 02Denka Company Limited to Report Q1, 2026 Results on Aug 07, 2025Denka Company Limited announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 13+ 3 more updatesDenka Company Limited, Annual General Meeting, Jun 20, 2025Denka Company Limited, Annual General Meeting, Jun 20, 2025.お知らせ • Mar 12Oriental Shiraishi Corporation (TSE:1786) signed a share transfer agreement to acquire 51% stake in Denka Renotec Co., Ltd. from Denka Company Limited (TSE:4061).Oriental Shiraishi Corporation (TSE:1786) signed a share transfer agreement to acquire 51% stake in Denka Renotec Co., Ltd. from Denka Company Limited (TSE:4061) on March 12, 2025. Even after the transfer of shares, Denka Renotec will remain an equity-method affiliate of Denka Company Limited.お知らせ • Dec 03Denka Company Limited to Report Q3, 2025 Results on Feb 07, 2025Denka Company Limited announced that they will report Q3, 2025 results on Feb 07, 2025お知らせ • Sep 27Denka Company Limited to Report Q2, 2025 Results on Nov 08, 2024Denka Company Limited announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Jun 15Denka Company Limited to Report Q1, 2025 Results on Aug 07, 2024Denka Company Limited announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • May 12Denka Company Limited, Annual General Meeting, Jun 20, 2024Denka Company Limited, Annual General Meeting, Jun 20, 2024.お知らせ • Apr 24Denka Company Limited (TSE:4061) agreed to acquire 50% stake in Frontier Carbon Corporation from Mitsubishi Corporation (TSE:8058).Denka Company Limited (TSE:4061) agreed to acquire 50% stake in Frontier Carbon Corporation from Mitsubishi Corporation (TSE:8058) on April 24, 2024.お知らせ • Mar 02Denka Company Limited to Report Fiscal Year 2024 Results on May 10, 2024Denka Company Limited announced that they will report fiscal year 2024 results on May 10, 2024お知らせ • Dec 09Denka Company Limited to Report Q3, 2024 Results on Feb 07, 2024Denka Company Limited announced that they will report Q3, 2024 results on Feb 07, 2024お知らせ • Sep 02Denka Company Limited to Report Q2, 2024 Results on Nov 08, 2023Denka Company Limited announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Jun 09Denka Company Limited to Report Q1, 2024 Results on Aug 07, 2023Denka Company Limited announced that they will report Q1, 2024 results on Aug 07, 2023お知らせ • May 13Denka Company Limited, Annual General Meeting, Jun 22, 2023Denka Company Limited, Annual General Meeting, Jun 22, 2023.お知らせ • Nov 27Denka Company Limited to Report Q3, 2023 Results on Feb 07, 2023Denka Company Limited announced that they will report Q3, 2023 results on Feb 07, 2023財務状況分析短期負債: DENK.Fの 短期資産 ( ¥252.8B ) が 短期負債 ( ¥194.5B ) を超えています。長期負債: DENK.Fの短期資産 ( ¥252.8B ) が 長期負債 ( ¥148.1B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: DENK.Fの 純負債対資本比率 ( 61.3% ) は 高い と見なされます。負債の削減: DENK.Fの負債対資本比率は、過去 5 年間で53.3%から71.1%に増加しました。債務返済能力: DENK.Fの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 12.9% )。インタレストカバレッジ: DENK.Fの負債に対する 利息支払い は EBIT ( 22.4 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/03 19:10終値2025/12/04 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Denka Company Limited 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Takashi EnomotoBofA Global ResearchAtsushi IkedaCitigroup IncHidemitsu UmebayashiDaiwa Securities Co. Ltd.11 その他のアナリストを表示
お知らせ • May 13Denka Company Limited, Annual General Meeting, Jun 19, 2026Denka Company Limited, Annual General Meeting, Jun 19, 2026.
お知らせ • Apr 22+ 3 more updatesDenka Company Limited to Report Q2, 2027 Results on Nov 09, 2026Denka Company Limited announced that they will report Q2, 2027 results on Nov 09, 2026
お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.
お知らせ • Mar 10Denka Company Limited (TSE:4061) enter into a share transfer agreement to acquire an additional 15% stake in Toyo Styrene Co. Ltd from Daicel Corporation (TSE:4202).Denka Company Limited (TSE:4061) enter into a share transfer agreement to acquire an additional 15% stake in Toyo Styrene Co. Ltd from Daicel Corporation (TSE:4202) on March 9, 2026. Upon completion, Denka Company Limited will own 65% stake in Toyo Styrene Co. Ltd. As a result of this transaction, Toyo Styrene is expected to become a consolidated subsidiary of the Company that qualifies as a specified subsidiary. Daicel will cease to be a co-investor in Toyo Styrene, and Toyo Styrene’s Hirohata Plant will be shut down. For a certain period, however, Toyo Styrene will continue to outsource production to Daicel and maintain product sales. For the period ending March 31, 2025, Toyo Styrene Co. Ltd reported total revenue of ¥48.39 billion, EBIT of ¥1.22 billion and net income of ¥788 million. As of March 31, 2025, Toyo Styrene Co. Ltd reported total assets of ¥27.69 billion and total common equity of ¥11.73 billion. The completion of this share transfer is subject to the completion of the necessary approvals, permissions, or clearances from the relevant authorities in accordance with the Anti-Monopoly Act and other applicable laws and regulations. The expected completion of the transaction is March 31, 2026.
お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.
お知らせ • Dec 24Denka Company Limited to Report Q3, 2026 Results on Feb 06, 2026Denka Company Limited announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 22Denka Company Limited(TSE:4061) dropped from FTSE All-World Index (USD)Denka Company Limited(TSE:4061) dropped from FTSE All-World Index (USD)
お知らせ • Sep 03Denka Company Limited to Report Q2, 2026 Results on Nov 10, 2025Denka Company Limited announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • Jul 02Denka Company Limited to Report Q1, 2026 Results on Aug 07, 2025Denka Company Limited announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 13+ 3 more updatesDenka Company Limited, Annual General Meeting, Jun 20, 2025Denka Company Limited, Annual General Meeting, Jun 20, 2025.
お知らせ • Mar 12Oriental Shiraishi Corporation (TSE:1786) signed a share transfer agreement to acquire 51% stake in Denka Renotec Co., Ltd. from Denka Company Limited (TSE:4061).Oriental Shiraishi Corporation (TSE:1786) signed a share transfer agreement to acquire 51% stake in Denka Renotec Co., Ltd. from Denka Company Limited (TSE:4061) on March 12, 2025. Even after the transfer of shares, Denka Renotec will remain an equity-method affiliate of Denka Company Limited.
お知らせ • Dec 03Denka Company Limited to Report Q3, 2025 Results on Feb 07, 2025Denka Company Limited announced that they will report Q3, 2025 results on Feb 07, 2025
お知らせ • Sep 27Denka Company Limited to Report Q2, 2025 Results on Nov 08, 2024Denka Company Limited announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Jun 15Denka Company Limited to Report Q1, 2025 Results on Aug 07, 2024Denka Company Limited announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • May 12Denka Company Limited, Annual General Meeting, Jun 20, 2024Denka Company Limited, Annual General Meeting, Jun 20, 2024.
お知らせ • Apr 24Denka Company Limited (TSE:4061) agreed to acquire 50% stake in Frontier Carbon Corporation from Mitsubishi Corporation (TSE:8058).Denka Company Limited (TSE:4061) agreed to acquire 50% stake in Frontier Carbon Corporation from Mitsubishi Corporation (TSE:8058) on April 24, 2024.
お知らせ • Mar 02Denka Company Limited to Report Fiscal Year 2024 Results on May 10, 2024Denka Company Limited announced that they will report fiscal year 2024 results on May 10, 2024
お知らせ • Dec 09Denka Company Limited to Report Q3, 2024 Results on Feb 07, 2024Denka Company Limited announced that they will report Q3, 2024 results on Feb 07, 2024
お知らせ • Sep 02Denka Company Limited to Report Q2, 2024 Results on Nov 08, 2023Denka Company Limited announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Jun 09Denka Company Limited to Report Q1, 2024 Results on Aug 07, 2023Denka Company Limited announced that they will report Q1, 2024 results on Aug 07, 2023
お知らせ • May 13Denka Company Limited, Annual General Meeting, Jun 22, 2023Denka Company Limited, Annual General Meeting, Jun 22, 2023.
お知らせ • Nov 27Denka Company Limited to Report Q3, 2023 Results on Feb 07, 2023Denka Company Limited announced that they will report Q3, 2023 results on Feb 07, 2023